Myriad Genetics (MYGN) Other Non-Current Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Other Non-Current Liabilities data on file, last reported at $1.7 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.7 million, down 15.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (down 15.0% YoY), and the FY2025 annual result was $1.9 million, down 13.64% from the prior year.
• Other Non-Current Liabilities fell to $1.7 million in Q1 2026 per MYGN's latest filing, from $1.9 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $48.1 million in Q4 2023 and troughed at $1.7 million in Q3 2025.
• A 5-year average of $19.8 million and a median of $11.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 253.04% in 2024 and fell as far as 95.43% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $43.9 million in 2022, then advanced by 9.57% to $48.1 million in 2023, then sank by 95.43% to $2.2 million in 2024, then retreated by 13.64% to $1.9 million in 2025, then decreased by 10.53% to $1.7 million in 2026.
• Business Quant data shows MYGN's Other Non-Current Liabilities at $1.7 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.